New peer-reviewed data reinforce that C2N’s PrecivityAD2™ blood test offers high accuracy in detecting brain amyloid pathology in patients with cognitive symptoms. According to the company, the test achieved 91 % accuracy, 90 % sensitivity, and 92 % specificity when compared against amyloid PET imaging as the reference standard.
Published in npj Dementia, the research focuses on individuals with mild cognitive impairment or dementia and supports the test’s ability to confirm Alzheimer’s disease pathology in symptomatic populations. The company claims these results align with the 2025 Alzheimer’s Association clinical practice guidelines, which recommend confirmatory blood biomarker tests meeting ≥ 90 % thresholds for accuracy, sensitivity, and specificity.
C2N states that PrecivityAD2 integrates plasma biomarkers Aβ42/40 and phosphorylated tau-217 into an algorithm called Amyloid Probability Score (APS2™) to classify the presence or absence of amyloid plaques. The test is offered in 49 U.S. states (excluding New York pending certification) and has ongoing international partnerships to expand access in Asia, Latin America, Europe, and the Middle East.
The company also highlights that prior large-scale studies published in JAMA validated the test’s performance in primary care and specialist settings, showing consistency when compared with cerebrospinal fluid and PET-based methods. C2N says its assays operate from a CAP-accredited, CLIA-certified laboratory under ISO 13485 standards.
